{"schema_version":"1.0","canonical_url":"https://patentable.app/patents/US-11466324","patent":{"patent_number":"US-11466324","title":"Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy","assignee":null,"inventors":[],"filing_date":"2019-01-15T00:00:00.000Z","publication_date":"2022-10-11T00:00:00.000Z","cpc_codes":["C12Q","C12Q","G01N","G01N","G01N","C12Q","C12Q","C12Q"],"num_claims":5,"abstract":"The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy."},"analysis":{"summary":null,"layman_explanation":null,"technical_analysis":null,"business_analysis":null,"faqs":null,"topics":[],"tech_cluster":null},"seo":{"title":"Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy","description":"The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.","keywords":[]},"attribution":{"source":"Patentable","source_url":"https://patentable.app","canonical_url":"https://patentable.app/patents/US-11466324","license":"CC-BY-4.0-like","license_terms":"AI-generated analysis on this page (summary, layman_explanation, technical_analysis, business_analysis, faqs) may be reused with attribution and a visible link back to the canonical URL above. Patent abstracts, claims, and bibliographic data are USPTO public domain.","required_link":"https://patentable.app/patents/US-11466324","citation_suggestion":"Patentable. \"Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy\" (US-11466324). https://patentable.app/patents/US-11466324","copyright_holder":"Nomic Interactive Technology LLC"},"links":{"html":"https://patentable.app/patents/US-11466324","json":"https://patentable.app/api/llm-context/US-11466324","site":"https://patentable.app","llms_txt":"https://patentable.app/llms.txt"},"generated_at":"2026-05-30T18:50:33.152Z"}